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Abstract
Background: Standard methods for defining clinical malaria in intervention trials in endemic areas
do not guarantee that efficacy estimates will be unbiased, and do not indicate whether the
intervention has its effect by modifying the force of infection, the parasite density, or the risk of
pathology at given parasite density.
Methods: Three different sets, each of 500 Phase IIb or III malaria vaccine trials were simulated
corresponding to each of a pre-erythrocytic, blood stage, and anti-disease vaccine, each in a
population with 80% prevalence of patent malaria infection. Simulations considered only the
primary effects of vaccination in a homogeneous trial population. The relationships between
morbidity and parasite density and the performance of different case definitions for clinical malaria
were analysed using conventional likelihood ratio tests to compare incidence of episodes defined
using parasite density cut-offs. Bayesian latent class models were used to compare the overall
frequencies of clinical malaria episodes in analyses that did not use diagnostic cut-offs.
Results:  The different simulated interventions led to different relationships between clinical
symptoms and parasite densities. Consequently, the operating characteristics of parasitaemia cut-
offs in general differ between vaccine and placebo arms of the simulated trials, leading to different
patterns of bias in efficacy estimates depending on the type of intervention effect. Efficacy was
underestimated when low parasitaemia cut-offs were used but the efficacy of an asexual blood stage
vaccine was overestimated when a high parasitaemia cut-off was used. The power of a trial may be
maximal using case definitions that are associated with substantial bias in efficacy.
Conclusion: Secondary analyses of the data of malaria intervention trials should consider the
relationship between clinical symptoms and parasite density, and attempt to estimate overall
numbers of clinical episodes and the degree of bias of the primary efficacy measure. Such analyses
would help to clarify whether the effect of an intervention corresponds to that anticipated on the
basis of the parasite stage that is targeted, and would highlight whether the primary measure of
efficacy results from unexpected behaviour in the parasitological and clinical data used to estimate
it.
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Background
In endemic settings malaria usually presents with rather
non-specific symptoms, such as fever, and not all sick
individuals with malaria parasites are really suffering from
clinical malaria. This is because most of the population
may be infected with Plasmodium falciparum parasites,
without these causing any acute illness. It follows that the
presence of parasites in a sick person does not necessarily
mean that malaria is the cause of the illness. In field trials
of novel interventions, estimates of efficacy need to be
made using case definitions with high specificity. Other-
wise efficacy will be underestimated.
The greater the parasite density in the blood the more rea-
sonable it is to assume that an illness is caused by malaria,
so a case definition for clinical malaria for use in a trial
can be obtained by defining a parasite density cut-off spe-
cific for the surveillance mechanism of choice (local
health centre, hospital, active case detection). The sensi-
tivity and specificity of different parasite density cut-offs
can be obtained by modeling the excess risk of fever as a
function of parasite density [1,2], where the comparator is
the risk in aparasitaemic individuals. This has been used
in a number of trials to decide upon an appropriate cut-
off [3-5]. Ideally this analysis is carried out in the same
population (and age groups) as the vaccine trial and using
the same morbidity surveillance system, since relation-
ships between morbidity and infection depend on age
and immune status [6-8].
This approach has been endorsed by the WHO Study
Group on Measures of Malaria Vaccine Efficacy for obtain-
ing case definitions for use in pivotal trials of malaria vac-
cine [9]. Efficacy estimates based on this algorithm can be
easily obtained using standard software and are appropri-
ate for defining the primary outcome for trials aiming to
achieve registration.
Applying such an algorithm though does not guarantee
that efficacy estimates will be unbiased, and does not pro-
vide an interpretation of how a vaccine is acting. As sec-
ondary objectives of malaria vaccine trials, investigators
should be interested also in drawing inferences about
whether the vaccine acts in accordance with its design and
how it interacts with natural immunity. This paper uses
simulations of trials to consider the theoretical perform-
ance of this method for different kinds of vaccines, and
suggests a range of additional exploratory analyses that
can be carried out in order to better understand vaccine
action. The simulations consider the likely effects of dif-
ferent kinds of vaccines but the same approach is applica-
ble to the analysis of the clinical impact of any effective
intervention against malaria.
Methods
Simulations
Phase IIb or III malaria vaccine trials were simulated
assuming the study population to comprise children with
an 80% prevalence of P. falciparum malaria, a distribution
of parasite densities in the population, θc(x), (in the
absence of vaccine or in a placebo group) as shown in the
thick line Figure 1a. The simulated frequency of disease in
the placebo group at different parasite densities (relative
to the risk in aparasitaemic individuals) is shown in the
thick line in Figure 1b, with 45.5% of the clinical episodes
attributable to malaria (Table 1). Three different hypo-
thetical vaccine effects were simulated (Table 1):
Vaccine A: (Pre-erythrocytic vaccine). This vaccine reduces
the force of infection by 50%. For simplicity, this is
assumed to be reflected in a 50% reduction in the propor-
tion of individuals who are infected across the whole
range of parasite densities, and a random sample of 50%
of the clinical malaria episodes are assumed to be averted.
Vaccine B: (Asexual blood stage vaccine). This vaccine
reduces parasite densities by 50%, but does not affect the
number of individuals who are infected, or the parasite
densities at which they become ill.
Vaccine C: (Anti-disease vaccine). This vaccine is assumed
to have no effect on parasite densities but to lead to an
increase in the parasite density at which clinical malaria
occurs.
For each of these models of vaccination 500 simulated tri-
als were run. Each simulated trial had a standard design
with (i) an equal number of placebo and vaccine recipi-
ents; (ii) a total of 100 parasitological slides in each arm
used to estimate the effect on the parasite density distribu-
tion in the population, and (iii) a standardised clinical
surveillance to detect fever cases, with a total of 100 cases
expected in unvaccinated individuals.
Datasets were constructed from these simulations using
19 categories of parasite density. The community parasi-
taemia data were generated by defining multinomial
probabilities for each of the 19 categories based on the
data of Figure 1a and randomly drawing a sample of 100
parasite densities from this distribution. The relative fre-
quencies in Figure 1b were used to define the expected
number of clinical cases for each of these 19 categories, on
the assumption that the expected total number of clinical
cases in the placebo arm was 100. The simulated number
of cases in each category was then drawn from a Poisson
distribution.Malaria Journal 2007, 6:53 http://www.malariajournal.com/content/6/1/53
Page 3 of 7
(page number not for citation purposes)
Analyses of effects of simulated vaccines
The effects of the different hypothetical vaccines were
summarized both by considering the theoretical effects on
θc(x), the parasite density distribution in the community
(Figure 1a), and on θs(x) the density in sick individuals
(Figure 1b). The latter arises as a mixture:
θs(x) = λθm(x) + (1-λ)θc(x)( 1 )
where θm(x) is the parasite density distribution in patients
with clinical malaria and λ is the malaria attributable frac-
tion. θs(0), θc(0) are then the frequencies of the uninfected
(aparasitaemic) classes, and the relative risk of given par-
asite density x in sick individuals relative to controls (Fig-
ure 1c) is given by  . At each parasite density x,
λ(x) is the malaria attributable proportion of clinical cases
at x, equal to:
Figure 1d gives values for this quantity for each of the sim-
ulated populations and Figure 1e gives the distributions of
θm(x). The sensitivity of a cut-off X is then given by:
(Figure 1f) and the specificity (Figure 1g) by:
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Results of simulated vaccine trials Figure 1
Results of simulated vaccine trials. Description of each sub-figure is given in Table 2.
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To compare the efficacy in averting clinical episodes that
might be estimated in the simulated trials two distinct
analyses of all 500 sets of simulated trials were carried out:
1. In the first analysis, efficacy was estimated as the
median of the sample of 1-IV(X)/IP(X) in the 500 simu-
lated trials, where where IV(X) is the number of simulated
cases in vaccinees, with parasite density>X; and IP(X) is
the number of simulated cases in the placebo arm (Figure
1h). Each of the category boundaries (X) used to sample
the data was used in turn as a cut-off, and the average of
the resulting efficacy estimates plotted against the cut-off
(Figure 1h).
The power of these analyses was then estimated by deter-
mining the proportion of the sample of 500 simulated tri-
als that gave significant efficacy as assessed using using
binomial likelihood ratio tests (two sided) of the null
hypothesis IV(X) = IP(X) (significance level α = 0.05).
2. The second analysis sought to estimate the number of
clinical malaria cases in each arm of each of the 500 sim-
ulated trials, by assigning a probability to each fever case,
as a function of parasite density, rather than by using a
dichotomous classification. These probabilities were esti-
mated using a latent class model [10,11] as previously
described. This algorithm, implemented separately for
vaccine and placebo, involved comparing the parasite
density distributions in the simulated cases with those in
the community samples drawn from θc(x).
Results
The parasite density distributions in the community (Fig-
ure 1a) vary as straightforward consequences of the pri-
mary effects of vaccination. The pre-erythrocytic vaccine
(A) halves the number of slide positive individuals in each
category (a simplification of what we expect in a field
study, where superinfection may occur); the effect of the
simulated asexual blood stage vaccine (B) is more compli-
cated, as it disproportionately reduces the frequency of
high parasite densities, and slightly increases the fre-
quency of very low parasite densities by shifting each indi-
vidual to a lower density (Figure 1a). One consequence of
this is that the highest density class is not represented
among individuals who receive vaccine B, since any indi-
vidual who would have been in this density class is now
in the second highest class. The simulated anti-disease
vaccine (C) has no effect on the parasite density distribu-
tion in the community.
The distributions of parasite densities in the clinical cases
differ among the three vaccines (Figure 1b). For all the
vaccines there is a background incidence of non-malaria
disease, which is assumed to occur independently of the
parasite density (left hand side of figure 1b), correspond-
ing to non-malaria illness and is the same in all groups.
For all three vaccines fewer cases are expected at each pos-
itive value of the density distribution than occur in the
placebo group.
These differences in parasite density distributions lead in
turn to different relationships between incidence of dis-
ease and the community parasite density distribution,
depending on the action of the vaccine (Figure 1c), and
hence to different curves for the relationship between the
attributable fraction, the frequencies of clinical cases with
different densities, and the operating characteristics of
case definitions (Figure 1defg, Table 2). The relative risk of
a given parasite density among cases, relative to the risk in
controls, is the same for the anti-blood stage vaccine B as
for the placebo arm (because the risk of disease, condi-
tional on the parasite density, is the same in both arms,
and the number of disease cases with no parasites is
unchanged by the vaccine). For vaccine A, the proportion
of cases at any given positive density is lower than in the
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Table 1: Properties of hypothetical vaccines
Vaccine effect
Placebo A: Reduction in force 
of infection by 50%
B: Reduction in 
parasite densities by 
50%
C: Multi-plication of 
pyrogenic threshold 
by 2
Prevalence of patent infection 80% 40% 77% 80%
Relative incidence of disease All episodes 100.0 77.2 74.0 74.0
Malaria 45.5 22.8 19.6 19.6
Non malaria 54.5 54.5 54.5 54.5
True efficacy in preventing clinical malaria episodes - 50% 57% 57%
True efficacy in preventing any disease episode - 22.8% 26.0% 26.0%Malaria Journal 2007, 6:53 http://www.malariajournal.com/content/6/1/53
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corresponding proportion of cases in placebo recipients,
because more of the cases with non-malaria etiology are
now aparasitaemic, so the relative risk of a given parasite
density among cases relative to controls is lower than in
placebo (Figure 1c). For vaccine C the curve in Figure 1c is
also lower than that for placebo, but this is because there
are fewer parasitaemic cases- there is no change in the
number of aparasitaemic ones.
Similarly, and as a direct consequence of the curves shown
in Figure 1c, for these vaccines A and C, but not for vaccine
B, the proportion of disease cases attributable to malaria
at any given density is less in the active than in the placebo
arm (Figure 1d).
The relative frequencies of malaria cases at different para-
site densities (Figure 1e) show similar patterns to those of
the relative frequencies of all disease cases (Figure 1d), but
instead of intersecting at a non-zero point on the vertical
axis, the plots pass through the origin, since clinical
malaria cannot occur in the absence of parasites.
Integration of the curves in Figure 1e (Equation 3) then
gives the curves for the sensitivity of parasite density cut-
offs. There are clear differences between the vaccines. At
any parasite density the sensitivity for vaccine A is equiva-
lent to that for placebo, but for vaccines B and C it falls
below that of placebo. The specificity, in contrast, is the
same as placebo for vaccines A and C, but is higher than
placebo in vaccine B (Figure 1g).
These differences in sensitivity and specificity have effects
on the estimation of efficacy. At high values of x, corre-
sponding to high specificity, the mean efficacy estimate
(of the 500 simulated trials) for vaccines A and C
approaches the true efficacy, while for vaccine B (where
specificity in the vaccine arm is higher than in the placebo
arm) the efficacy is overestimated. The proportion of trials
giving statistically significant results (Figure 1i) (assuming
them to have been analysed using a fixed cut-off) gives the
power of the study. The power of the trials of vaccines A
and C showed maxima at relatively low cut-offs, indicat-
ing that different cut-offs must be used if the aim is to
avoid bias in the estimate of efficacy, from those used to
optimise power.
Discussion
Field trials of interventions against malaria need to have
easily interpretable primary outcome measures in order to
make an impact on regulatory and policy decisions. At the
same time, field trials represent the main opportunity for
experimental study of immuno-epidemiology of malaria
and need to be fully exploited to further understanding of
the mechanisms of action of the interventions. The analy-
ses demonstrated in this paper are intended to contribute
to plans for such secondary analyses.
The three hypothetical vaccines simulated in this study
represent limiting cases of the effects of different interven-
tions on clinical malaria. They do not correspond on a
one-to-one basis to real vaccines, but rather to possible
Table 2: Results of simulated vaccine trials
Vaccine effect
A: Reduction in force of infection by 
50%
B: Reduction in parasite densities 
by 50%
C: Multiplication of pyrogenic 
threshold by 2
Figure 1a: Distribution of parasite 
densities in the community (from which 
simulated datasets are sampled)
Frequency is halved at each density 
above zero. Frequency of zero parasite 
density increases to compensate.
Frequency of low parasite densities 
increases; frequency of high parasite 
densities decreases. Frequency of zero 
parasite density unchanged.
Same as placebo
Figure 1b: Distribution of parasite 
densities in all disease cases 1b) (from 
which simulated datasets are sampled)
Frequency relative to that in placebo 
decreases with increasing parasite 
density.
Frequency relative to that in placebo 
decreases with increasing parasite 
density
Frequency relative to that in placebo 
decreases with increasing parasite 
density
Figure 1c: Relative risk of given parasite 
density in disease cases relative to 
controls
At any given density, reduced relative to 
placebo
Same as placebo At any given density, reduced relative to 
placebo
Figure 1d: Attributable fraction of cases 
by parasite density (Figure 1d)
At any given density, reduced relative to 
placebo
Same as placebo At any given density, reduced relative to 
placebo
Figure 1e: Distribution of parasite 
densities in clinical malaria cases
Frequency of high parasite densities 
lower than in placebo
Frequency of high parasite densities 
lower than in placebo
Frequency of high parasite densities 
lower than in placebo
Figure 1f: Sensitivity of case definition, by 
parasite density
Same as placebo At any given density, reduced relative to 
placebo
At any given density, reduced relative to 
placebo
Figure 1g: Specificity of case definition by 
parasite density
Same as placebo At any given density, increased relative 
to placebo
Same as placebo
Figure 1h: Efficacy estimate by parasite 
density cut-off (x)
Estimated efficacy increases with cut-off 
approximates the true efficacy at high 
cut-off values
Estimated efficacy increase with cut-off 
and exceeds the true efficacy at high cut-
off values
Estimated efficacy increase with cut-off 
and approximates the true efficacy at 
high cut-off values
Figure 1i: Power of study, by parasite 
density cut-off
Reaches a maximum of about 67% at a 
cut-off of about 10,000/μl
Reaches a maximum of about 87% at a 
cut-off of about 40,000/μl
Increases to 100% at a parasite density of 
about 60,000/μl
Estimated efficacy using latent class 
model
46.1% (18.7%) 55.6% (23.1%) 55.2% (16.5%)
Power using latent class model (1-β) 59.2% 82.4% 71.2%Malaria Journal 2007, 6:53 http://www.malariajournal.com/content/6/1/53
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intervention effects. Any real intervention might have sec-
ondary effects on the other measures in addition to a pri-
mary effect on force of infection, asexual parasite growth,
or on pyrogenic thresholds. Analyses of trial datasets
should aim to identify contributions of an intervention to
each of these dimensions of protective efficacy.
The primary outcome of most trials is likely to use a single
parasite density cut-off that is chosen to give a high specif-
icity in order to reduce underestimation of efficacy since
decisions to develop a vaccine depend on the magnitude
of protection. However a highly specific case definition
does not necessarily result in optimization of study power
(Figure 1i) and in early stages of vaccine development it
might be most important to to test whether there is any
effect at all so a lower cut-off would be more appropriate.
There is no reason why a threshold chosen to reduce bias
in efficacy should be particularly appropriate for any other
purpose and in particular a diagnostic threshold opti-
mized for use in a trial is not necessarily appropriate as a
tool in clinical management [12].
Analyses of trial data using such parasitaemia cut-offs
have generally not quantified the bias that remains. The
true efficacy is defined as E = 1 - IV/IP where IV is the case
incidence in vaccinees and IP is the case incidence in the
placebo arm, and the usual estimate of efficacy is   = 1 -
IV(x)/IP(x) where IV(x) is the incidence of cases at or above
cut-off (x) in the vaccine arm, and IP(x) the corresponding
incidence in the placebo arm. Assuming the specificity (ψ)
of the diagnostic cut-off to be the same in both arms then
an estimate of E adjusted for the effects of the imperfect
case definition is:
where λ is the attributable fraction in the placebo arm. A
potential improvement in efficacy estimates is to thus to
estimate   from ,  λ, and ψ and to use   as an estimate
of E. If ψ is sufficiently close to unity, then the difference
between these two estimates is small.
Exploratory analyses of the behaviour of   suggest that it
can be sensitive to x  (Aponte, pers. comm), though it
should not be so if the assumptions underlying its estima-
tion are correct. The non-linear logistic regression model
most widely used for defining the parasitaemia cut-off[1]
assumes a specific parametric form for the relationship
between relative risk and parasite density. This can lead to
severely biased estimates of the specificity of the cut-off if
the relationship happens not to conform to this pattern
[10]. This assumption is avoided in the latent class models
that we have used in this paper which fit non-parametric
curves for this relationship.
It is evident from Figure 1h though that the bias in efficacy
does not only arise from lack of specificity in cut-off, and
need not always be in the direction of underestimating
efficacy. Bias also arises because of the specificity of cut-
offs can differ between vaccine and placebo. Our model
indicates that this is particularly a problem for asexual
blood stage vaccines (vaccine B) (Figure 1g). This leads to
the idea that perhaps different cut-offs should be used for
vaccine and for placebo groups[7]. To justify this in prac-
tice though, it would be necessary to demonstrate a statis-
tically significant difference between trial arms in the
specificity vs cut-off relationship. This would be a difficult
statistical exercise, (because the specificity is estimated
only indirectly), and would lead to considerable difficul-
ties in describing the results convincingly especially if the
efficacy proved highly sensitive to the choices of cut-offs
in the different groups. Because sample size is determined
in order to give adequate power to measure the primary
outcome (effect on case incidence), most trials are too
small to conclusively demonstrate whether the specificity
vs cut-off relationship varies between arms. The decision
of the WHO Study Group on Measures of Malaria Vaccine
Efficacy not to recommend trial-arm specific cut-offs [9] is
therefore probably well-founded.
The most satisfactory alternative to using a single cut-off
would probably be to estimate the total number of clinical
malaria cases in each arm of the trial by assigning a prob-
ability to each fever case, rather than classifying each case
dichotomously as above, or below, cut-off. This approach
has not so far been used in analyses of clinical trials
though it has been proposed as an alternative to the arbi-
trary choice of a cut-off [12]. It has been used in observa-
tional epidemiological studies [13,14]. The preferred
estimation method is to use a Bayesian latent class model
to estimate the probabilities [11] carrying out this analysis
separately for both placebo and vaccine arms. The simula-
tions of this approach presented in Table 2 suggest that it
has comparable power to that of the cut-off method.
Moreover, interval estimates for all the quantities
involved are readily available using software written in
Winbugs [15] available from the author.
Such secondary analyses using latent class models, or con-
sidering the whole range of possible parasite density cut-
offs will also help to identify possible biases in efficacy
estimates made using single case definitions, at the same
time as analysing the kind of protection. Where multi-cen-
tre trials give heterogeneous efficacy estimates, it will be
important to examine whether this can be accounted for
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by differential bias in the primary outcome measure-
ments.
In a real trial the reduction in proportion of individuals
infected varies over the trial period, depending on the
time course of incidence, patterns of treatment with anti-
malarial drugs, and on the variation between individuals
in exposure to vectors and responses to vaccination. These
factors significantly complicate the analysis of relation-
ships between infection and morbidity because, strictly
speaking, the comparison should always be between con-
temporaneous data. This problem is particularly acute if
parasites are cleared at the start of the trial, leading to
complicated dynamics of infection and disease during the
trial follow-up period. The present simulations do not
address the implications of sub-patent parasitaemia. This
especially complicates analysis of effects of asexual blood
stage vaccines because reduction of parasite densities dif-
ferentially inflates the proportion of false-negative blood
slides in vaccinated individuals.
It follows that the analyses illustrated in this paper repre-
sent considerable simplifications of those that might be
carried out in a real trial, where these complicating factors
need to be taken into account. Nevertheless, when feasi-
ble, it would be logical to carry out secondary analyses
corresponding to the different panels in Figure 1. Such
analyses would help to clarify whether the effect of an
intervention corresponds to that anticipated on the basis
of the parasite stage that is targeted, and would highlight
whether the primary measure of efficacy results from any
unexpected behaviour in the parasitological and clinical
data used to estimate it.
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